📊 SSKN Key Takeaways
Is STRATA Skin Sciences, Inc. (SSKN) a Good Investment?
STRATA is in severe financial distress with persistent operating losses (-15.3% margin), negative free cash flow (-$4.3M), and minimal equity ($2.9M) supporting extreme leverage (5.28x debt-to-equity). Declining revenue (-8.5% YoY), liquidity deterioration (0.58x current ratio), and inability to service debt (negative interest coverage) present acute solvency risk.
Why Buy STRATA Skin Sciences, Inc. Stock? SSKN Key Strengths
- Gross margin of 58.3% indicates reasonable product economics and pricing power
- Cash position of $7.9M provides near-term operational buffer
- Net loss improved 37.9% YoY, indicating some operational improvement trajectory
SSKN Stock Risks: STRATA Skin Sciences, Inc. Investment Risks
- Persistent unprofitability: -$6.3M net income, -15.3% operating margin, -20.4% net margin
- Extreme leverage with minimal equity cushion: $15.3M debt on $2.9M equity (5.28x debt-to-equity ratio)
- Negative free cash flow generation (-$4.3M) indicates cash burn despite gross profitability
- Deteriorating liquidity: current ratio 0.58x, quick ratio 0.48x (both below 1.0 threshold)
- Negative interest coverage (-9.0x) and inability to cover debt service from operations
- Declining revenue (-8.5% YoY) undermines recovery narrative
- Zero insider buying activity in 90 days suggests confidence deficit
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Revenue stabilization and return to growth
- Debt refinancing ability and covenant compliance status
- Gross margin sustainability amid revenue decline
STRATA Skin Sciences, Inc. (SSKN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SSKN Profit Margin, ROE & Profitability Analysis
SSKN vs Healthcare Sector: How STRATA Skin Sciences, Inc. Compares
How STRATA Skin Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is STRATA Skin Sciences, Inc. Stock Overvalued? SSKN Valuation Analysis 2026
Based on fundamental analysis, STRATA Skin Sciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
STRATA Skin Sciences, Inc. Balance Sheet: SSKN Debt, Cash & Liquidity
SSKN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: STRATA Skin Sciences, Inc.'s revenue has grown significantly by 12% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.10 indicates the company is currently unprofitable.
SSKN Revenue Growth, EPS Growth & YoY Performance
SSKN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.9M | -$91.0K | $-0.03 |
| Q2 2025 | $7.7M | -$99.0K | $-0.03 |
| Q1 2025 | $6.8M | -$2.4M | $-0.58 |
| Q3 2024 | $8.8M | -$99.0K | $-0.30 |
| Q2 2024 | $8.3M | -$99.0K | $-0.03 |
| Q1 2024 | $6.8M | -$2.8M | $-0.08 |
| Q3 2023 | $8.9M | -$995.0K | $-0.03 |
| Q2 2023 | $8.3M | -$1.9M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
STRATA Skin Sciences, Inc. Dividends, Buybacks & Capital Allocation
SSKN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for STRATA Skin Sciences, Inc. (CIK: 0001051514)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SSKN
What is the AI rating for SSKN?
STRATA Skin Sciences, Inc. (SSKN) has an AI rating of STRONG SELL with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SSKN's key strengths?
Claude: Gross margin of 58.3% indicates reasonable product economics and pricing power. Cash position of $7.9M provides near-term operational buffer.
What are the risks of investing in SSKN?
Claude: Persistent unprofitability: -$6.3M net income, -15.3% operating margin, -20.4% net margin. Extreme leverage with minimal equity cushion: $15.3M debt on $2.9M equity (5.28x debt-to-equity ratio).
What is SSKN's revenue and growth?
STRATA Skin Sciences, Inc. reported revenue of $30.7M.
Does SSKN pay dividends?
STRATA Skin Sciences, Inc. does not currently pay dividends.
Where can I find SSKN SEC filings?
Official SEC filings for STRATA Skin Sciences, Inc. (CIK: 0001051514) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SSKN's EPS?
STRATA Skin Sciences, Inc. has a diluted EPS of $-1.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SSKN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, STRATA Skin Sciences, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SSKN stock overvalued or undervalued?
Valuation metrics for SSKN: ROE of -215.3% (sector avg: 15%), net margin of -20.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SSKN stock in 2026?
Our dual AI analysis gives STRATA Skin Sciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SSKN's free cash flow?
STRATA Skin Sciences, Inc.'s operating cash flow is $-2.8M, with capital expenditures of $1.5M. FCF margin is -13.9%.
How does SSKN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -20.4% (avg: 12%), ROE -215.3% (avg: 15%), current ratio 0.58 (avg: 2).
Is STRATA Skin Sciences, Inc. carrying too much debt?
SSKN has a debt-to-equity ratio of 5.28x, which is above the Healthcare sector average of 0.6x. Combined with a current ratio below 1, this warrants careful monitoring of the balance sheet.